Phio Pharmaceuticals Corp. PHIO
0.81 USD -0.03 (-3.11%)
At closeNov 10, 2026, 4:00 PM EST
0.80 -0.01 -1.70%
After hours · Nov 10, 4:00 PM ET
0.7902 Day range 0.86
0.75 52-week range 1.88
- YTD
- -22.50%
- 1 year
- -47.50%
News
newsfilecorp.com Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)…
newsfilecorp.com Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
newsfilecorp.com Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA…
feeds.newsfilecorp.com Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
defenseworld.net Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b Phio Pharmaceuticals (NASDAQ: PHIO) is advancing its lead immuno-oncology candidate, PH-762, as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, President and Chief Executive…
feeds.newsfilecorp.com Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile
newsfilecorp.com Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. -…
newsfilecorp.com Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp.…
feeds.newsfilecorp.com Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
newsfilecorp.com Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp.…
benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
benzinga.com Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) -…
feeds.newsfilecorp.com Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
newsfilecorp.com Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP…
newsfilecorp.com Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA…
newsfilecorp.com Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA…
newsfilecorp.com Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is…- benzinga.com Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio's global intellectual property portfolio in the…
newsfilecorp.com Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp.…
newsfilecorp.com Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA…
benzinga.com Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
feeds.newsfilecorp.com Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical- benzinga.com Phio Pharmaceuticals Commences Manufacturing The First Commercial-scale Batch Of PH-762 Drug Substance At Nitto Denko Avecia Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in June 2025. Under the agreement to date, Avecia has successfully concluded a series of important…
newsfilecorp.com Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical trial in next development phase King of Prussia,…
feeds.newsfilecorp.com Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of…
benzinga.com Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
benzinga.com Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous carcinomas. In its Phase 1b trial, Phio has reported that 22 patients…- benzinga.com Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% response rate. Analysts maintain Buy ratings as shares trade near 52-week lows.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
- benzinga.com Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO)…
- benzinga.com Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
- benzinga.com Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10 percent. This is a 71.43 percent increase over losses of $(1.54)…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05 Pricing On 4.65M Shares Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today…
benzinga.com Why Is Phio Pharmaceuticals Stock Soaring Today? Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…